In addition, those who received the entry inhibitor had a mean increase in CD4+ cells of 110 cells/μL in the once-daily group, 106 cells/μL in the twice-daily group, and 56 cells/μL in the placebo group.Maraviroc was approved for medical use in the European Union in September 2007. Names Maraviroc is the International nonproprietary name (INN). Research Maraviroc appears to reduce graft-versus-host disease in people treated with allogeneic bone marrow transplantation for leukemia, in a Phase I/II study. References Further reading External links Entry inhibitors Pfizer brands Carboxamides Hepatotoxins Triazoles Tropanes